Sponsors (17)
The bill aims to improve diagnosis, care continuity, and benefits alignment for veterans with blast exposures by creating a VA–DoD Task Force and targeted research/baseline programs, but it imposes administrative costs and risks shifting research priorities or creating stricter evaluation practices that could delay some claims.
Veterans and service members with blast exposure will receive more coordinated clinical care and benefits alignment through a joint VA–DoD Task Force that centralizes expertise and oversight.
Veterans and affected service members will get improved diagnosis and treatment as the bill establishes physiological and cognitive baselines and prioritizes translational research on TBI, neuroinflammation, vestibular dysfunction, and related conditions.
Veterans will benefit from better continuity of care and long-term monitoring because the measure supports integration of mobile and longitudinal diagnostic tools into follow-up and care pathways.
Veterans could face new or stricter evidentiary or evaluation approaches that, if implemented rigidly, risk delaying some disability claims or creating barriers to benefits.
Taxpayers and VA/DoD budgets will incur administrative costs to establish and run the Task Force through 2029, which could divert resources from other programs or services for veterans.
Prioritizing specific blast-related research areas may divert limited research funding away from other veteran health issues not named in the bill, potentially leaving some conditions less studied.
Based on analysis of 2 sections of legislative text.
Introduced December 4, 2025 by Ronny Jackson · Last progress December 4, 2025
Creates a VA–DoD Blast Overpressure Task Force to coordinate research, clinical care, and benefits evaluation for service members and veterans exposed to blast overpressure. The Task Force must be stood up within 180 days, prioritize translational research in specified areas (sleep, gut health, mobile diagnostics, balance, autonomic dysfunction, cumulative mild TBI, neuroinflammation, etc.), establish physiological and cognitive baselines, support longitudinal and mobile diagnostics, and issue annual reports with recommendations on clinical practice and VA claims evaluation; it terminates on September 30, 2029.